Latest / Stock Picking with Fexingo: Individual Equities, Research, and Building a Concentrated Portfolio
How Pfizer's Dividend Became a Trap in June 2026
Pfizer's stock has fallen 7.3% in five days and the dividend yield is over 10%. Lucas and Luna examine how the pharma giant's post-Covid revenue collapse has turned what looked like a stable income stock into a high-risk value trap. They walk through the numbers: the dividend payout ratio, the patent cliff, and the pipeline risks. Plus, they contrast Pfizer with JPMorgan's $50 billion buyback announced this week, asking which approach signals better capital discipline. A sharp case study in why yield alone is never the story.
#Pfizer #DividendStocks #ValueTrap #PharmaStocks…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.